<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05127135</url>
  </required_header>
  <id_info>
    <org_study_id>ThisCART7</org_study_id>
    <nct_id>NCT05127135</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of ThisCART7 in Patients With Refractory or Relapsed T Cell Malignancies</brief_title>
  <official_title>A Study to Evaluate the Safety and Clinical Activity of Allogeneic CAR-T Targeting CD7 in Patients With Refractory or Relapsed T Cell Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundamenta Therapeutics, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The First Affiliated Hospital of University of Science and Technology of China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundamenta Therapeutics, Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single dose escalation study to evaluate the safety and clinical activity of&#xD;
      ThisCART7(Allogeneic CAR-T targeting CD7) in patients with refractory or relapsed CD7&#xD;
      positive T cell malignancies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center, nonrandomized, open-label, dose-escalation study to evaluate the&#xD;
      safety and clinical activity of ThisCART7 in patients with refractory or relapsed CD7&#xD;
      positive T cell malignancies, such as T-cell Acute Lymphoblastic Leukemia, T-cell Acute&#xD;
      Lymphoblastic Lymphoma and T-cell Non-Hodgkin Lymphoma. The dose range is 0.5-6 x 10^6 cells&#xD;
      per kg body weight.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 22, 2020</start_date>
  <completion_date type="Anticipated">December 24, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 24, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-related grade≥3Adverse Events or SAE</measure>
    <time_frame>within 4 weeks after infusion</time_frame>
    <description>Therapy-related adverse events or SAE will be recorded and assessed according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE, Version 5.0).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>4 to 6 weeks after infusion</time_frame>
    <description>Description:&#xD;
For T-ALL, Objective response rate(ORR) is the percentage of patients who achieve CR or CRi, determined by National Comprehensive Cancer Network (NCCN) clinical practice guidelines in oncology Acute Lymphoblastic Leukemia (2020.V1) ;&#xD;
For lymphoma, ORR is the incidence of either a complete response (CR) or a partial response (PR). Response will be assessed using the 2014 Lugano criteria.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Progression free survival time</measure>
    <time_frame>3 years</time_frame>
    <description>The interval between administration and disease progression or death.</description>
  </other_outcome>
  <other_outcome>
    <measure>Overall survival time</measure>
    <time_frame>3 years</time_frame>
    <description>The interval between administration and death caused by any reason.</description>
  </other_outcome>
  <other_outcome>
    <measure>Event-free survival</measure>
    <time_frame>3 years</time_frame>
    <description>EFS is calculated from administration to death, progression of the disease, relapse or gene recurrence, whichever comes first, or last visit.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>T-Acute Lymphoblastic Leukemia</condition>
  <condition>T-cell Non-Hodgkin Lymphoma</condition>
  <condition>T-cell Acute Lymphoblastic Lymphoma</condition>
  <arm_group>
    <arm_group_label>ThisCART7 cells injections</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this study, allogeneic anti-CD7 CAR T Cells(ThisCART7 cells) is used to treat patients with refractory or relapsed CD7 positive T cell malignancies.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ThisCART7 cells</intervention_name>
    <description>0.5-6 x 10^6 CAR T cells per kg body weight</description>
    <arm_group_label>ThisCART7 cells injections</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosed with relapsed and refractory CD7 + T cell hematologic malignancies&#xD;
             (including, but not limited to, T-cell leukemia, extranodal NK/ T-cell lymphoma nasal,&#xD;
             peripheral T-cell lymphoma, enteropathy associated T-cell lymphoma and anaplastic&#xD;
             T-cell lymphoma, etc.);&#xD;
&#xD;
          2. No alternative treatment options deemed by investigator;&#xD;
&#xD;
          3. Measurable or detectble disease at time of enrollment;&#xD;
&#xD;
          4. Age 18-70 years old, no gender and race limited;&#xD;
&#xD;
          5. Eastern cooperative oncology group (ECOG) performance status of ≤2;&#xD;
&#xD;
          6. Cardiac ejection fraction ≥ 40%, no evidence of pericardial effusion as determined by&#xD;
             an echocardiogram (ECHO);&#xD;
&#xD;
          7. Estimated life expectancy &gt; 12 weeks deemed by investigator;&#xD;
&#xD;
          8. Serum creatinine ≤ 1.5 upper limit of normal (ULN);&#xD;
&#xD;
          9. Serum ALT/ AST ≤ 5 upper limit of normal (ULN);&#xD;
&#xD;
         10. Signed informed consent form (ICF).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Women in pregnancy or lactation;&#xD;
&#xD;
          2. Uncontrolled infection;&#xD;
&#xD;
          3. Active hepatitis B virus or hepatitis C virus infection;&#xD;
&#xD;
          4. Concurrent use of corticosteroids or other immunosuppressant medications for chronic&#xD;
             disease;&#xD;
&#xD;
          5. Prior treatment with an allogeneic stem cell transplant within 100 days;&#xD;
&#xD;
          6. Grade 2-4 Active graft versus host disease;&#xD;
&#xD;
          7. History of HIV infection;&#xD;
&#xD;
          8. With central nervous system involvement;&#xD;
&#xD;
          9. Patients combine with other disease cause neutrophil count (ANC) &lt; 750/uL or PLT&lt;&#xD;
             50,000/uL.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wang Xingbing</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of USTC (Anhui Provincial Hospital)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Li Jun, Ph.D</last_name>
    <phone>+86-18662604088</phone>
    <email>jli@ctigen.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>He Ling</last_name>
    <phone>+86-18626100886</phone>
    <email>lhe@ctigen.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First Affiliated Hospital of USTC (Anhui Provincial Hospital)</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xingbing Wang</last_name>
      <phone>+86-18056075256</phone>
      <email>wangxingbing@ustc.edu.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundamenta Therapeutice Co.,Ltd</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Li</last_name>
      <phone>+8618662604088</phone>
      <email>jli@ctigen.com</email>
    </contact>
    <contact_backup>
      <last_name>Ling He</last_name>
      <phone>+8618626100886</phone>
      <email>lhe@ctigen.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 9, 2021</study_first_submitted>
  <study_first_submitted_qc>November 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2021</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Precursor T-Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

